<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04159103</url>
  </required_header>
  <id_info>
    <org_study_id>mRNA-3927-P101</org_study_id>
    <nct_id>NCT04159103</nct_id>
  </id_info>
  <brief_title>Open Label Study of mRNA-3927 in Patients With Propionic Acidemia</brief_title>
  <official_title>A Global, Phase 1/2, Open-label, Dose Escalation Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of mRNA-3927 in Participants With Propionic Acidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ModernaTX, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ModernaTX, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This First-in-Human (FIH) Phase 1/2 study will evaluate mRNA-3927 in patients 1 year of age
      and older with propionic acidemia (PA). The study is designed to characterize baseline
      biomarker levels followed by assessment of safety, pharmacokinetics, and pharmacodynamics of
      different doses of mRNA-3927 in patients affected by PA as part of the Dose Escalation phase.

      During the Dose Escalation phase, three dose levels of mRNA-3927 are planned to be
      investigated in this study among patients with PA: low dose, mid dose, and high dose. An
      additional three cohorts to evaluate other dose levels and/or dosing intervals may be
      considered jointly by the independent SMC and the Sponsor.

      Upon establishment of a dose with acceptable safety and pharmacodynamic activity, additional
      patients will be enrolled in a Dose Expansion phase to allow for further characterization of
      the safety and pharmacodynamics of mRNA-3927.

      Patients in both phases of study will participate in a pre-dosing observational period,
      followed by a treatment period, and then a follow-up period after withdrawal of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Day 1 (initial mRNA-3927 dose) through 104 weeks after last mRNA-3927 dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plasma 2-MC levels</measure>
    <time_frame>Week -3 through Week 36 after initial mRNA-3927 dose</time_frame>
    <description>Baseline (pre-dose levels) to post-dose levels measured after single and after repeated administrations of mRNA-3927 including estimation of pharmacodynamic (PD) parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plasma 3-HP levels</measure>
    <time_frame>Week -3 through Week 36 after initial mRNA-3927 dose</time_frame>
    <description>Baseline (pre-dose levels) to post-dose levels measured after single and after repeated administrations of mRNA-3927 including estimation of pharmacodynamic (PD) parameters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) after administration of mRNA-3927</measure>
    <time_frame>Baseline through Week 36</time_frame>
    <description>Baseline (pre-dose levels) to post-dose levels measured after single and after repeated administrations of mRNA-3927</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Cmax (Tmax)</measure>
    <time_frame>Baseline through Week 36</time_frame>
    <description>Baseline (pre-dose levels) to post-dose levels measured after single and after repeated administrations of mRNA-3927</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>Baseline through Week 36</time_frame>
    <description>Baseline (pre-dose levels) to post-dose levels measured after single and after repeated administrations of mRNA-3927</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of anti-polyethylene glycol antibodies</measure>
    <time_frame>Baseline through Week 104</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Propionic Acidemia</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Phase: Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mRNA-3927</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Phase: Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mRNA-3927</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Phase: Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mRNA-3927</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: Dose Expansion Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mRNA-3927</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mRNA-3927</intervention_name>
    <description>mRNA-3927 dispersion for intravenous (IV) infusion</description>
    <arm_group_label>Dose Escalation Phase: Dose Level 1</arm_group_label>
    <arm_group_label>Dose Escalation Phase: Dose Level 2</arm_group_label>
    <arm_group_label>Dose Escalation Phase: Dose Level 3</arm_group_label>
    <arm_group_label>Experimental: Dose Expansion Phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant must be ≥ 1 year of age at the time of consent/assent (Inclusion of the
             first three participants entering the study at the Dose Escalation stage will be
             restricted to individuals age ≥ 8 years)

          -  Confirmed diagnosis of propionic acidemia based on diagnosis by molecular genetic
             testing (PCCA and/or PCCB mutations)

        Exclusion Criteria:

          -  Estimated glomerular filtration rate &lt;30 mL/min/1.73 m2, as estimated by Schwartz
             formula (Schwartz et al 2012); or participants who receive chronic dialysis

          -  History of organ transplantation or planned organ transplantation during the period of
             study participation

          -  QTc &gt;480 ms using Bazett's correction

          -  Grade 3 or 4 heart failure according to the Modified Ross Heart Failure Classification
             for Children or the New York Heart Association
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 7, 2019</study_first_submitted>
  <study_first_submitted_qc>November 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2019</study_first_posted>
  <last_update_submitted>November 8, 2019</last_update_submitted>
  <last_update_submitted_qc>November 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mRNA-3927</keyword>
  <keyword>Propionic Aciduria</keyword>
  <keyword>Metabolism, Inborn Errors</keyword>
  <keyword>Genetic Diseases</keyword>
  <keyword>Inborn Amino Acid Metabolism, Inborn Errors</keyword>
  <keyword>Acidosis</keyword>
  <keyword>Acid-Base Imbalance</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Organic Acidemias</keyword>
  <keyword>Moderna</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propionic Acidemia</mesh_term>
    <mesh_term>Acidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

